May 5, 2015
On Monday, May 18, advocates around the world will observe HIV Vaccine Awareness Day (HVAD)—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. We invite you to join us on the day for a webinar—Vaccines in Vivo: Advances in AIDS Vaccine Research
—at 10am US ET / 4pm South Africa / 5pm East Africa time (check www.timeanddate.com
for your local time). We are also updating materials for vaccine advocates, including our “HVAD Toolkit
” for those interested in easy-to-digest research updates.
This year brought the launch of long-awaited initiation of clinical trials building on positive results from the RV144 “Thai” trial
. This effort is led by the Pox-Protein Public-Private Partnership (P5), including the the HIV Vaccine Trials Network
, who will join the webinar to provide a status update of their current vaccine research and development program. We will also feature Janssen
, part of Johnson & Johnson, to provide an overview of the research program they are moving forward that focuses on a cross-clade vaccine product.
Join this webinar if you’d like to understand:
Click to register for the webinar.
This webinar will be the next installment in our Prevention on the Line
series, a year-long dialogue on pressing issues in HIV prevention research and implementation.
For advocates planning HVAD activities or simply looking for an update on the latest in the field, AVAC is updating its “HVAD Toolkit”, which includes a range of materials with HIV vaccine research highlights. The updated Toolkit will be available shortly at www.avac.org/hvad
. Please email us
if you're looking for a specific resource right away.
We look forward to commemorating another HVAD with all of you as we continue to work toward the ultimate goal of a vaccine to prevent HIV. AVAC would especially like to thank the Bill & Melinda Gates Foundation
, International AIDS Vaccine Initiative
, the US Agency for International Development
, and our civil society partners in countries for supporting and partnering in HVAD and other vaccine advocacy initiatives.
We look forward to hearing your voices and questions in this discussion. And, as always, please email us at email@example.com
with questions, comments and suggestions.